Our researchers should be jumping for joy. Now we just need our Great stroke association to push some of the 177 hyperacute possibilities thru this delivery method. With that in place we could significantly reduce the disability from strokes. Ask your doctor for their ideas on how to reduce stroke damage. If none are forthcoming, ask yourself why you are seeing someone so incurious.
Delivery time in 10-20 minutes. Now if you could objectively determine that an ischemic stroke occurred you could have tPA delivered via this method in the ambulance.
http://www.xconomy.com/seattle/2013/04/18/uw-spinoff-impel-neuropharma-passes-key-nose-to-brain-clinical-trial/
Seattle-based Impel Neuropharma
has been working for five years to show it can quickly deliver drugs
through the nose, directly to the brain, for the treatment of central
nervous system disorders. The animal data so far has been encouraging,
but now the company has got key confirmation that it can do its thing in
human beings.
Impel,
a University of Washington spinoff, is announcing today that it has
gotten those positive results from a study of seven patients, which was
supported by one of its pharmaceutical collaborators. Full details are
being saved for a peer-reviewed publication, but Impel chief scientist
John Hoekman says that the company’s nose-to-brain drug delivery device
was able to propel a small peptide molecule deep into the upper nasal
passages and to the brain stem at an “order of magnitude” greater
concentration than a conventional nasal spray.
The study enrolled research subjects at the Lovelace Respiratory Research Institute
in Albuquerque, NM, Hoekman says. Researchers used an off-the-shelf
peptide (not an actual drug candidate), attached to a radioactive tracer
molecule, and used noninvasive SPECT
imaging technology to confirm that the drug was getting delivered to
the brain. Volunteers in the study were able to self-administer the
compound through the nose, and researchers saw it get delivered to the
destination within 10 to 20 minutes, Hoekman says.
More at link.
No comments:
Post a Comment